The main objective is to assess the benefit-risk ratio of a risk-adapted strategy for treatment of extra cranial NSMGCT in children and adolescent.

Two different situations will be considered:

• in NSMGCT patients treated with cisplatin-based chemotherapy, the objective is to maintain a 2-year progression-free survival rate >80% despite a limitation of the number of course of chemotherapy (≤4) after the achievement of a clinical and biological response (primary endpoint);
• in children over 10 years with testicular or extragonadal NSMGCT, the objective is to improve the overall survival by systematically classifying the patients in high-risk group to allow a dose intensification.

Inclusion Criteria:

• Extra cranial non seminomateous malignant germ cell tumour (NSMGCT) except pure immature teratoma.
• Age ≤ 18 years.
• Affiliation with a social security scheme.
• Signed informed consent by parents
• Effective contraception during the study if relevant .

Exclusion Criteria:

• Previous chemotherapy
• Contraindications to study treatments
• Patient who cannot follow medical surveillance due to geographical, social, or psychological reasons
• Pregnant and breast feeding women